Everand Logo

Welcome to Everand!

  • STAT

    This biotech CEO’s lousy job performance cost shareholders money, so his board docked his pay

    Corporate boards often pay lip service to real governance. At one biotech, directors docked the CEO's pay.
    by Adam Feuerstein Apr 30, 2018 1 minute
    Source: APStock

    The board of directors at Acorda Therapeutics has docked the pay of CEO Ron Cohen for a series of missteps that hobbled the drug maker last year.

    Cohen was due to receive a 2017 bonus of just under $255,000 — about half

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min readCrime & Violence
    STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
    A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.

    Related Books & Audiobooks